The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT02710747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Registry
-
NCT02710747
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02710747. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
- Acronym
- POWAT
- Condition
- Heart Valve Disease
- Condition
- Older Than 18-years-old
- Condition
- Without Any Liver or Kidney Diseases
- Intervention (Genetic)
- CYP2C9;VKORC1
- Lead sponsor
- Guangdong Provincial People's Hospital
Record details
- Record id
cardio:ct-nct02710747- Content hash
25e1323dbb44a98ef26fc1375db2726420322e98e9c66cffa092f66d19d66be5